ORIC Pharmaceuticals, Inc.

113 articles about ORIC Pharmaceuticals, Inc.

• ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences - Nov 11, 2021

  11/11/2021

  ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that management will participate in the following investor conferences.

• ORIC Pharmaceuticals Appoints Angie You, Ph.D., to its Board of Directors

  11/10/2021

  ORIC Pharmaceuticals, Inc. today announced the appointment of Angie You, Ph.D., to its board of directors.

• ORIC Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Update

  11/8/2021

  ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today reported financial results and operational updates for the quarter ended September 30, 2021.

• ORIC Pharmaceuticals to Present Update on CD73 Inhibitor Program in Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting

  11/4/2021

  ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced a preclinical poster presentation at the American Society of Hematology Annual Meeting to be held December 11-14, 2021, in Atlanta, GA.

• 

  Clinical Catch-Up: October 4-8

  10/11/2021

  Another busy week for clinical trial news. Here’s a look.

• ORIC Pharmaceuticals Presents Initial Clinical Data from Phase 1b Trial of ORIC-101 in Combination with Enzalutamide and Preclinical Data on ORIC-114 at AACR-NCI-EORTC

  10/7/2021

  ORIC Pharmaceuticals, Inc. today announced multiple presentations, including initial clinical data from an ongoing Phase 1b study evaluating ORIC-101, a glucocorticoid receptor antagonist, in combination with enzalutamide, in patients with metastatic prostate cancer progressing on enzalutamide.

• ORIC Pharmaceuticals Announces Multiple Data Presentations at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

  9/30/2021

  ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced three poster presentations at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics to be held October 7-10, 2021.

• ORIC Pharmaceuticals Announces Update on ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor

  9/21/2021

  ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced an update on its CD73 inhibitor program.

• ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences in September 2021

  9/1/2021

  ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that management will participate in the following investor conferences in September:

• ORIC Pharmaceuticals Appoints Steven L. Hoerter to its Board of Directors

  8/16/2021

  ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced the appointment of 25-year industry veteran Steven L. Hoerter to its Board of Directors.

• ORIC Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update

  8/10/2021

  ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, reported financial results and operational updates for the quarter ended June 30, 2021.

• ORIC Pharmaceuticals Announces FDA Clearance of IND Application for ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor

  6/28/2021

  ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that the U.S. Food and Drug Administration has cleared the company’s Investigational New Drug Application for ORIC-533 to proceed into a first-in-human clinical trial.

• ORIC Pharmaceuticals Reports Initial Clinical Data Being Presented at ASCO from Phase 1b Trial of ORIC-101 in Combination with Nab-Paclitaxel

  6/2/2021

  ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced initial data from an ongoing Phase 1b study evaluating ORIC-101, a glucocorticoid receptor antagonist, in combination with nab-paclitaxel, in advanced solid tumors.

• ORIC Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference

  5/26/2021

  ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob Chacko, M.D., chief executive officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021, at 1:30 p.m. ET.

• ORIC Pharmaceuticals to Host Conference Call with KOL to Review Initial Data Being Presented at ASCO from Phase 1b Study of ORIC-101 in Combination with Nab-paclitaxel

  5/25/2021

  ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that the company will host a conference call and webcast to review initial data from the ongoing Phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with nab-paclitaxel in advanced solid tumors.

• ORIC Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update

  5/6/2021

  ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, reported financial results and operational updates for the quarter ended March 31, 2021.

• ORIC Pharmaceuticals to Present Initial Data from Ongoing Phase 1b Study of ORIC-101 in Combination with Nab-paclitaxel at the 2021 ASCO Annual Meeting

  4/28/2021

  ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that two abstracts highlighting preliminary results from the Phase 1b study of ORIC-101 in combination with nab-paclitaxel have been accepted for poster presentations during the 2021 American Society of Clinical Oncology Annual Meeting, to be held June 4 - 8, 2021.

• ORIC Pharmaceuticals Presents Posters on Four Programs at the 2021 American Association for Cancer Research (AACR) Annual Meeting

  4/12/2021

  ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of resistance in cancer, presented four preclinical poster presentations at the 2021 American Association for Cancer Research (AACR) virtual annual meeting.

• ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update

  3/23/2021

  ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today reported financial results and operational updates for the quarter and year ended December 31, 2020.

• ORIC Pharmaceuticals to Present Posters on Four Programs at the 2021 American Association for Cancer Research (AACR) Annual Meeting

  3/10/2021

  ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of resistance in cancer, announced four preclinical poster presentations at the 2021 American Association for Cancer Research virtual annual meeting on April 10-15, 2021.